Alphamab Oncology (FRA:3NK)

Alphamab Oncology Revenue

Alphamab Oncology had revenue of 319.44M CNY in the half year ending June 30, 2025, with 134.08% growth. This brings the company's revenue in the last twelve months to 785.96M, up 207.17% year-over-year. In the year 2024, Alphamab Oncology had annual revenue of 640.08M with 192.58% growth.

• Revenue (ttm): 785.96M CNY
• Revenue Growth: +207.17%
• P/S Ratio: 9.96
• Revenue / Employee: 1.62M CNY
• Employees: 484
• Market Cap: 930.10M EUR

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	640.08M	421.31M	192.58%
Dec 31, 2023	218.77M	51.93M	31.12%
Dec 31, 2022	166.85M	20.82M	14.26%
Dec 31, 2021	146.02M	-	-
Dec 31, 2020	-	-	-